Loading...
Market
How many new clinical trials for Ozempic in neurodegenerative diseases by end of 2025?
2
Resolution / Starting Odds
More than 5 trials • 25%
3 to 5 trials • 25%
1 to 2 trials • 25%
No new trials • 25%
Clinical trial registries such as ClinicalTrials.gov
Story
Ozempic Linked to 70% Lower Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 12:14 PM
Novo Nordisk's diabetes drug Ozempic, which contains the active ingredient semaglutide, has been linked to a significantly reduced risk of being diagnosed with Alzheimer's disease among people with type 2 diabetes. The observational study found a 70% lower risk of Alzheimer's diagnosis compared to other diabetes medications, based on an analysis of medical records. This adds to the growing evidence of Ozempic's effects beyond type 2 diabetes and obesity, indicating potential benefits in neurodegenerative diseases. Wegovy, another drug containing semaglutide, may also reduce Alzheimer's risk.
View original story
Similar markets
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Yes • 50%
No • 50%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%